Effects of antibody on viral kinetics in simian/human immunodeficiency virus infection: implications for vaccination.

Department of Haematology, Prince of Wales Hospital and Centre for Vascular Research, University of New South Wales, Kensington, New South Wales 2052, Australia.
Journal of Virology (Impact Factor: 4.65). 06/2004; 78(10):5520-2. DOI: 10.1128/JVI.78.10.5520-5522.2004
Source: PubMed

ABSTRACT Passive antibody treatment of macaques prior to simian/human immunodeficiency virus infection produces "sterilizing immunity" in some animals and long-term reductions in viral loads in others. Analysis of viral kinetics suggests that antibody mediates sterilizing immunity by its effects on the initial viral inoculum. By contrast, reduction in peak viral load later in infection prevents CD4 depletion and contributes to long-term viral control.

1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We propose a mathematical model to interpret observations concerning the behavior of broadly neutralizing antibodies for chronic HIV in vivo. The model enables us to identify a threshold antibody level that must be achieved to decrease the viral load effectively. Although this threshold has not been reached in existing passive immunization studies, it is within range of humoral immune responses, suggesting that therapeutic vaccines are feasible. In an appendix, we develop a model of passive immunization against influenza, and acute infection.
    Vaccine 11/2011; 30(3):607-13. DOI:10.1016/j.vaccine.2011.11.048 · 3.49 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: As socio-medical phenomena, epidemics are revealing of the cultures in which they are experienced. The HIV/AIDS epidemic in Africa exposes antecedent tensions between state and society, and, on a broader canvas, between the global north and south. As a contribution to the emerging literature on the social ramifications of HIV/AIDS, this article examines the saga of the Nigerian physician and immunologist, Dr Jeremiah Abalaka, who like other innovators in sub-Saharan Africa claims to have developed a curative HIV vaccine. Whilst articulating the social conditions that enabled Abalaka to thrive, the article explores the marked differences in the reaction to his "discovery" among state representatives, the scientific establishment, the general public, people living with HIV, and the media. Finally, the article valorizes the emergence of new actors in the African health sector, and the diversity of strategies used by ordinary people to achieve and maintain wellness.
    African Affairs 03/2011; 110(439):191-211. DOI:10.1093/afraf/adr001 · 1.54 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The importance of Fc-mediated effector function in protective immunity to HIV-1 (hereafter referred to simply as HIV) is becoming increasingly apparent. A large of number of studies in natural infection cohorts, spanning the last twenty-six years, have associated Fc-mediated effector function, particularly antibody-dependent cellular cytotoxicity (ADCC), with a favorable clinical course. These studies strongly suggest a role for Fc-mediated effector function in the post-infection control of viremia. More recently, studies in both humans and non-human primates (NHPs) also implicate Fc-mediated effector function in blocking HIV acquisition. Accordingly, this review will discuss the results supporting a role of Fc-mediated effector function in both blocking acquisition and post-infection control of viremia. Parallel studies in NHPs and humans will be compared for common themes. Context for this discussion will be provided by summarizing the temporal emergence of key host and virological events over the course of an untreated HIV infection framing where, when, and how Fc-mediated effector function might be protective. A hypothesis that Fc-mediated effector function protects primarily in the early stages of both acquisition and post-infection control of viremia will be developed. This article is protected by copyright. All rights reserved.
    Immunology 12/2013; DOI:10.1111/imm.12232 · 3.74 Impact Factor

Full-text (2 Sources)

Available from
May 29, 2014